<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genetic abnormalities and <z:e sem="disease" ids="C0021053" disease_type="Disease or Syndrome" abbrv="">immune system disorders</z:e> resulting from them are the causes of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic diseases</z:e> as well as <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e>, including <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the rearrangement of genes may not only be the cause of <z:hpo ids='HP_0002664'>neoplasms</z:hpo> but also the result of oncolytic treatment used </plain></SENT>
<SENT sid="2" pm="."><plain>One of the late treatment-related complications of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic diseases</z:e> is the development of a second <z:hpo ids='HP_0002664'>neoplasm</z:hpo> and possible disorders belonging to the group of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e>, for example <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The paper presents the case of a 13-year-old boy (K.G.) treated for a second <z:hpo ids='HP_0002664'>neoplasm</z:hpo>, complicated by <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was diagnosed with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> -- middle risk group (ALL-MRG) at the age of 3, treated according to the BFM 87 Protocol (<z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, daunoribicin, asparaginase, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="50667">mercaptopurine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, thioguanine, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>), and complete remission was achieved </plain></SENT>
<SENT sid="5" pm="."><plain>Eight years after the first line treatment the boy was diagnosed with the second neoplastic process -- pre-B <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL-L2 pre-B common +) </plain></SENT>
<SENT sid="6" pm="."><plain>The ALLIC 2002 Protocol (<z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, daunoribicin, asparaginase, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="50667">mercaptopurine</z:chebi>. <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, thioguanine, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>) was started </plain></SENT>
<SENT sid="7" pm="."><plain>On day 71 of the therapy, during <z:mpath ids='MPATH_58'>aplasia</z:mpath> of blood marrow following chemotherapy, <z:mp ids='MP_0001845'>inflammation</z:mp> of the caecum was diagnosed and <z:chebi fb="1" ids="6909">metronidazole</z:chebi> was introduced </plain></SENT>
<SENT sid="8" pm="."><plain>Once blood counts improved, the complaints decreased and with continued chemotherapy of Protocol M (<z:chebi fb="0" ids="50667">mercaptopurine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>), completely subsided </plain></SENT>
<SENT sid="9" pm="."><plain>The symptoms reappeared during the 2-week break before Protoco II </plain></SENT>
<SENT sid="10" pm="."><plain>The physical examination revealed the presence of a hard, painless <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> (3 x 10 cm) in the right iliac fossa </plain></SENT>
<SENT sid="11" pm="."><plain>Colonoscopy showed a cauliflower-like formation within the Mauchin's valve projecting to the caecum lumen </plain></SENT>
<SENT sid="12" pm="."><plain>The histopathological evaluation of the sections demonstrated a typical picture of <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> of the ileum was diagnosed, the treatment with dexamethazone (according to Protocol II) was instituted which led to complete regression of the iliac lesions </plain></SENT>
<SENT sid="14" pm="."><plain>Steroid therapy (<z:chebi fb="0" ids="8382">prednisone</z:chebi>) continued until the treatment supporting the remission according to Protocol ALLIC 2002 (<z:chebi fb="0" ids="50667">mercaptopurine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> orally) was initiated </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: The differential diagnosis of complications accompanying <z:hpo ids='HP_0002664'>neoplasms</z:hpo> should consider the <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e>; their atypical course may be masked by the treatment of the underlying disease </plain></SENT>
</text></document>